Portal de investigação
Distinguishing health-related parameters between metabolically healthy and metabolically unhealthy obesity in women
Autores da FMUP
Participantes de fora da FMUP
- Mendonça F.
- Soares P.
- Moreno T.
- Rodrigues I.
- Festas D.
- Pedro J.
- Varela A.
- Fernandes A.
- Fernandes R.
- Soares R.
- Costa E.L.
- Luís C.
Unidades de investigação
Abstract
Background: Obesity represents a global health crisis, yet a dichotomy is emerging with classification according to the metabolic state into metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). This study aimed to identify distinctive systemic clinical/endocrinological parameters between MHO individuals, employing a comprehensive comparative analysis of 50 biomarkers. Our emphasis was on routine analytes, ensuring cost-effectiveness for widespread use in diagnosing metabolic health. Subjects/methods: The study included 182 women diagnosed with obesity referred for bariatric surgery at the Endocrinology, Diabetes, and Metabolism Service of São João Hospital and University Centre in Portugal. MUO was defined by the presence of at least one of the following metabolic disorders: diabetes, hypertension, or dyslipidemia. Patients were stratified based on the diagnosis of these pathologies. Results: Significantly divergent health-related parameters were observed between MHO and MUO patients. Notable differences included: albumin (40.1 ± 2.2 vs 40,98 ± 2.6 g/L, p value = 0.017), triglycerides (110.7 ± 51.1 vs 137.57 ± 82.6 mg/dL, p value = 0.008), glucose (99.49 ± 13.0 vs 119.17 ± 38.9 mg/dL, p value < 0.001), glycated hemoglobin (5.58 ± 0.4 vs 6.15 ± 1.0%, p value < 0.001), urea (31.40 ± 10.0 vs 34.61 ± 10.2 mg/dL, p value = 0.014), total calcium (4.64 ± 0.15 vs 4.74 ± 0.17 mEq/L, 1 mEq/L = 1 mg/L, p value < 0.001), ferritin (100.04 ± 129.1 vs 128.55 ± 102.1 ng/mL, p value = 0.005), chloride (104.68 ± 1.5 vs 103.04 ± 2.6 mEq/L, p value < 0.001), prolactin (13.57 ± 6.3 vs 12.47 ± 7.1 ng/mL, p value = 0.041), insulin (20.36 ± 24.4 vs 23.87 ± 19.6 µU/mL, p value = 0.021), c peptide (3.78 ± 1.8 vs 4.28 ± 1.7 ng/mL, p value = 0.003), albumin/creatinine ratio (15.41 ± 31.0 vs 48.12 ± 158.7 mg/g creatinine, p value = 0.015), and whole-body mineral density (1.27 ± 0.1 vs 1.23 ± 0.1 g/cm2, p value = 0.016). Conclusions: Our findings highlight potential additional parameters that should be taken into consideration alongside the commonly used biomarkers for classifying metabolic health in women. These include albumin, urea, total calcium, ferritin, chloride, prolactin, c-peptide, albumin-creatinine ratio, and whole-body mineral density. Moreover, our results also suggest that MHO may represent a transitional phase preceding the development of the MUO phenotype. © The Author(s), under exclusive licence to Springer Nature Limited 2024.
Dados da publicação
- ISSN/ISSNe:
- 0307-0565, 1476-5497
- Tipo:
- Article
- Páginas:
- 1027-1035
- Link para outro recurso:
- www.scopus.com
International Journal of Obesity Nature Publishing Group
Documentos
- Não há documentos
Filiações
Keywords
- Adult; Biomarkers; Blood Glucose; Female; Humans; Middle Aged; Obesity; Obesity, Metabolically Benign; Portugal; albumin; biological marker; C peptide; calcium; chloride; creatinine; ferritin; glucose; glycated hemoglobin; hemoglobin A1c; insulin; prolactin; triacylglycerol; urea; biological marker; adult; albumin to creatinine ratio; Article; bariatric surgery; bone density; clinical feature; controlled study; cost effectiveness analysis; diabetes mellitus; dyslipidemia; female; human; hypertension; major clinical study; metabolic disorder; metabolically healthy obese; metabolically unhealthy obese; middle aged; obesity; phenotype; Portugal; statistical significance; blood; epidemiology; glucose blood level; metabolically benign obesity; metabolism; obesity
Financiamento
Proyectos asociados
Metabolic syndrome is a main determinant of quality of life after metabolic surgery
Investigador Principal: Paula Isabel Marques Simões de Freitas
Estudo Clínico Académico (Metabolic syndrome) . 2023
The impact of integrase inhibitors on the development of hepatic steatosis and fibrosis in HIV-monoinfected patients
Investigador Principal: Paula Isabel Marques Simões de Freitas
Estudo Clínico Académico (Hepatic Steatosis) . 2023
Obesity and Cancer: the profile of a population who underwent bariatric surgery
Investigador Principal: Paula Isabel Marques Simões de Freitas
Estudo Clínico Académico . 2021
The role of gut microbiota-host interaction in obesity and metabolic disturbances
Investigador Principal: Paula Isabel Marques Simões de Freitas
Estudo Clínico Académico . 2020
Citar a publicação
Mendonça F,Soares P,Moreno T,Freitas P,Rodrigues I,Festas D,Pedro J,Varela A,Fernandes A,Fernandes R,Soares R,Costa EL,Luís C. Distinguishing health-related parameters between metabolically healthy and metabolically unhealthy obesity in women. Int. J. Obes. 2024. 48. (7):p. 1027-1035. IF:4,900. (2).
